Atlas Trials

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Clinical trial NCT01017731 · COMPLETED

Trial details

NCT number
NCT01017731
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
CancerSolid Tumor
Start date
2009-11-01
Primary completion
2010-04-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.